Litcius/Paper detail

Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases

Yu Wang, Wei Long, Yan Cao, Jingyun Li, Lianghui You, Yuru Fan

2020Bioscience Reports28 citationsDOIOpen Access PDF

Abstract

Preterm birth is a complex syndrome and remains a substantial public health problem globally. Its common complications include periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). Despite great advances in the comprehension of the pathogenesis and improvements in neonatal intensive care and associated medicine, preterm birth-related diseases remain essentially without adequate treatment and can lead to high morbidity and mortality. The therapeutic potential of mesenchymal stem/stromal cells (MSCs) appears promising as evidenced by their efficacy in preclinical models of pathologies relevant to premature infant complications. MSC-based therapeutic efficacy is closely associated with MSC secretomes and a subsequent paracrine action response to tissue injuries, which are complex and abundant in response to the local microenvironment. In the current review, we summarize the paracrine mechanisms of MSC secretomes underlying diverse preterm birth-related diseases, including PVL, BPD, NEC and ROP, are summarized, and focus is placed on MSC-conditioned media (CM) and MSC-derived extracellular vesicles (EVs) as key mediators of modulatory action, thereby providing new insights for future therapies in newborn medicine.

Topics & Concepts

Mesenchymal stem cellStem cellChemistryBiologyCell biologyNeonatal Respiratory Health ResearchMesenchymal stem cell researchInfant Nutrition and Health
Mesenchymal stem cell-derived secretomes for therapeutic potential of premature infant diseases | Litcius